Pfizer Income from Continuous Operations 2010-2024 | PFE
Pfizer annual/quarterly income from continuous operations history and growth rate from 2010 to 2024. Income from continuous operations can be defined as a company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change
- Pfizer income from continuous operations for the quarter ending September 30, 2024 was $4.481B, a 287.65% decline year-over-year.
- Pfizer income from continuous operations for the twelve months ending September 30, 2024 was $4.305B, a 59.03% decline year-over-year.
- Pfizer annual income from continuous operations for 2023 was $2.172B, a 93.08% decline from 2022.
- Pfizer annual income from continuous operations for 2022 was $31.401B, a 39.81% increase from 2021.
- Pfizer annual income from continuous operations for 2021 was $22.459B, a 236.92% increase from 2020.
Pfizer Annual Income from Continuous Operations
(Millions of US $) |
| 2023 |
$2,172 |
| 2022 |
$31,401 |
| 2021 |
$22,459 |
| 2020 |
$6,666 |
| 2019 |
$10,738 |
| 2018 |
$3,861 |
| 2017 |
$21,353 |
| 2016 |
$7,229 |
| 2015 |
$6,975 |
| 2014 |
$9,119 |
| 2013 |
$11,410 |
| 2012 |
$9,021 |
| 2011 |
$7,860 |
| 2010 |
$8,318 |
| 2009 |
$8,529 |
Pfizer Quarterly Income from Continuous Operations
(Millions of US $) |
| 2024-09-30 |
$4,481 |
| 2024-06-30 |
$31 |
| 2024-03-31 |
$3,128 |
| 2023-12-31 |
$-3,335 |
| 2023-09-30 |
$-2,388 |
| 2023-06-30 |
$2,340 |
| 2023-03-31 |
$5,555 |
| 2022-12-31 |
$5,000 |
| 2022-09-30 |
$8,645 |
| 2022-06-30 |
$9,877 |
| 2022-03-31 |
$7,879 |
| 2021-12-31 |
$3,578 |
| 2021-09-30 |
$8,171 |
| 2021-06-30 |
$5,825 |
| 2021-03-31 |
$4,885 |
| 2020-12-31 |
$662 |
| 2020-09-30 |
$917 |
| 2020-06-30 |
$2,604 |
| 2020-03-31 |
$2,483 |
| 2019-12-31 |
$-5,887 |
| 2019-09-30 |
$7,680 |
| 2019-06-30 |
$5,056 |
| 2019-03-31 |
$3,889 |
| 2018-12-31 |
$-7,700 |
| 2018-09-30 |
$4,111 |
| 2018-06-30 |
$3,879 |
| 2018-03-31 |
$3,571 |
| 2017-12-31 |
$12,288 |
| 2017-09-30 |
$2,858 |
| 2017-06-30 |
$3,077 |
| 2017-03-31 |
$3,130 |
| 2016-12-31 |
$764 |
| 2016-09-30 |
$1,355 |
| 2016-06-30 |
$2,062 |
| 2016-03-31 |
$3,048 |
| 2015-12-31 |
$-166 |
| 2015-09-30 |
$2,130 |
| 2015-06-30 |
$2,635 |
| 2015-03-31 |
$2,376 |
| 2014-12-31 |
$1,257 |
| 2014-09-30 |
$2,676 |
| 2014-06-30 |
$2,921 |
| 2014-03-31 |
$2,265 |
| 2013-12-31 |
$2,631 |
| 2013-09-30 |
$2,588 |
| 2013-06-30 |
$3,575 |
| 2013-03-31 |
$2,616 |
| 2012-12-31 |
$1,308 |
| 2012-09-30 |
$2,989 |
| 2012-06-30 |
$3,000 |
| 2012-03-31 |
$1,724 |
| 2011-12-31 |
$790 |
| 2011-09-30 |
$2,325 |
| 2011-06-30 |
$2,521 |
| 2011-03-31 |
$2,224 |
| 2010-12-31 |
$2,994 |
| 2010-09-30 |
$856 |
| 2010-06-30 |
$2,454 |
| 2010-03-31 |
$2,014 |
| 2009-12-31 |
$658 |
| 2009-09-30 |
$2,879 |
| 2009-06-30 |
$2,263 |
| 2009-03-31 |
$2,729 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$142.241B |
$58.496B |
|
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
|
